Cargando…

High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk

The physiological cholesterol-lowering benefits of β-glucan have been well documented, however, whether modulation of gut microbiota by β-glucan is associated with these physiological effects remains unknown. The objectives of this study were therefore to determine the impact of β-glucan on the comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanan, Ames, Nancy P., Tun, Hein M., Tosh, Susan M., Jones, Peter J., Khafipour, Ehsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748052/
https://www.ncbi.nlm.nih.gov/pubmed/26904005
http://dx.doi.org/10.3389/fmicb.2016.00129
_version_ 1782415056845144064
author Wang, Yanan
Ames, Nancy P.
Tun, Hein M.
Tosh, Susan M.
Jones, Peter J.
Khafipour, Ehsan
author_facet Wang, Yanan
Ames, Nancy P.
Tun, Hein M.
Tosh, Susan M.
Jones, Peter J.
Khafipour, Ehsan
author_sort Wang, Yanan
collection PubMed
description The physiological cholesterol-lowering benefits of β-glucan have been well documented, however, whether modulation of gut microbiota by β-glucan is associated with these physiological effects remains unknown. The objectives of this study were therefore to determine the impact of β-glucan on the composition of gut microbiota in mildly hypercholesterolemic individuals and to identify if the altered microbiota are associated with bioactivity of β-glucan in improving risk factors of cardiovascular disease (CVD). Using a randomized, controlled crossover study design, individuals received for 5-week either a treatment breakfast containing 3 g high molecular weight (HMW), 3 g low molecular weight (LMW), 5 g LMW barley β-glucan, or wheat and rice. The American Heart Association (AHA) diet served as the background diet for all treatment groups. Phases were separated by 4-week washout periods. Fecal samples were collected at the end of each intervention phase and subjected to Illumina sequencing of 16S rRNA genes. Results revealed that at the phylum level, supplementation of 3 g/d HMW β-glucan increased Bacteroidetes and decreased Firmicutes abundances compared to control (P < 0.001). At the genus level, consumption of 3 g/d HMW β-glucan increased Bacteroides (P < 0.003), tended to increase Prevotella (P < 0.1) but decreased Dorea (P < 0.1), whereas diets containing 5 g LMW β-glucan and 3 g LMW β-glucan failed to alter the gut microbiota composition. Bacteroides, Prevotella, and Dorea composition correlated (P < 0.05) with shifts of CVD risk factors, including body mass index, waist circumference, blood pressure, as well as triglyceride levels. Our data suggest that consumption of HMW β-glucan favorably alters the composition of gut microbiota and this altered microbiota profile associates with a reduction of CVD risk markers. Together, our study suggests that β-glucan induced shifts in gut microbiota in a MW-dependent manner and that might be one of the underlying mechanisms responsible for the physiological benefits of β-glucan.
format Online
Article
Text
id pubmed-4748052
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-47480522016-02-22 High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk Wang, Yanan Ames, Nancy P. Tun, Hein M. Tosh, Susan M. Jones, Peter J. Khafipour, Ehsan Front Microbiol Microbiology The physiological cholesterol-lowering benefits of β-glucan have been well documented, however, whether modulation of gut microbiota by β-glucan is associated with these physiological effects remains unknown. The objectives of this study were therefore to determine the impact of β-glucan on the composition of gut microbiota in mildly hypercholesterolemic individuals and to identify if the altered microbiota are associated with bioactivity of β-glucan in improving risk factors of cardiovascular disease (CVD). Using a randomized, controlled crossover study design, individuals received for 5-week either a treatment breakfast containing 3 g high molecular weight (HMW), 3 g low molecular weight (LMW), 5 g LMW barley β-glucan, or wheat and rice. The American Heart Association (AHA) diet served as the background diet for all treatment groups. Phases were separated by 4-week washout periods. Fecal samples were collected at the end of each intervention phase and subjected to Illumina sequencing of 16S rRNA genes. Results revealed that at the phylum level, supplementation of 3 g/d HMW β-glucan increased Bacteroidetes and decreased Firmicutes abundances compared to control (P < 0.001). At the genus level, consumption of 3 g/d HMW β-glucan increased Bacteroides (P < 0.003), tended to increase Prevotella (P < 0.1) but decreased Dorea (P < 0.1), whereas diets containing 5 g LMW β-glucan and 3 g LMW β-glucan failed to alter the gut microbiota composition. Bacteroides, Prevotella, and Dorea composition correlated (P < 0.05) with shifts of CVD risk factors, including body mass index, waist circumference, blood pressure, as well as triglyceride levels. Our data suggest that consumption of HMW β-glucan favorably alters the composition of gut microbiota and this altered microbiota profile associates with a reduction of CVD risk markers. Together, our study suggests that β-glucan induced shifts in gut microbiota in a MW-dependent manner and that might be one of the underlying mechanisms responsible for the physiological benefits of β-glucan. Frontiers Media S.A. 2016-02-10 /pmc/articles/PMC4748052/ /pubmed/26904005 http://dx.doi.org/10.3389/fmicb.2016.00129 Text en Copyright © 2016 Wang, Ames, Tun, Tosh, Jones and Khafipour. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Wang, Yanan
Ames, Nancy P.
Tun, Hein M.
Tosh, Susan M.
Jones, Peter J.
Khafipour, Ehsan
High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk
title High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk
title_full High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk
title_fullStr High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk
title_full_unstemmed High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk
title_short High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk
title_sort high molecular weight barley β-glucan alters gut microbiota toward reduced cardiovascular disease risk
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748052/
https://www.ncbi.nlm.nih.gov/pubmed/26904005
http://dx.doi.org/10.3389/fmicb.2016.00129
work_keys_str_mv AT wangyanan highmolecularweightbarleybglucanaltersgutmicrobiotatowardreducedcardiovasculardiseaserisk
AT amesnancyp highmolecularweightbarleybglucanaltersgutmicrobiotatowardreducedcardiovasculardiseaserisk
AT tunheinm highmolecularweightbarleybglucanaltersgutmicrobiotatowardreducedcardiovasculardiseaserisk
AT toshsusanm highmolecularweightbarleybglucanaltersgutmicrobiotatowardreducedcardiovasculardiseaserisk
AT jonespeterj highmolecularweightbarleybglucanaltersgutmicrobiotatowardreducedcardiovasculardiseaserisk
AT khafipourehsan highmolecularweightbarleybglucanaltersgutmicrobiotatowardreducedcardiovasculardiseaserisk